Top

Published in:

Open Access 01-12-2013 | Research

Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes

Authors: Fei Wang, Ye Guo, Qian Chen, Zhuo Yang, Ning Ning, Yujuan Zhang, Yonggang Xu, Xiaodong Xu, Chunrong Tong, Li Chai, Wei Cui

Published in: Journal of Hematology & Oncology | Issue 1/2013

Abstract

Background

Myelodysplastic syndromes (MDS) are a group of heterogeneous diseases with variable clinical course. Predicting disease progression is difficult due to lack of specific molecular marker(s). SALL4 plays important roles in normal hematopoiesis and leukemogenesis. SALL4 transgenic mice develop MDS prior to acute myeloid leukemia (AML) transformation. However, the role of SALL4 in human MDS has not been extensively investigated. In this study, we evaluate the diagnostic/prognostic value of SALL4 in MDS by examining its expression levels in a cohort of MDS patients.

Methods

Fifty-five newly diagnosed MDS, twenty MDS-AML, and sixteen post-treatment MDS patients were selected for our study along with ten healthy donors.

Results

We demonstrated that SALL4 was over-expressed in MDS patients and proportionally increased in MDS patients with high grade/IPSS scores. This expression pattern was similar to that of Bmi-1, an important marker in predicting MDS/AML progression. In addition, the level of SALL4 was positively correlated with increased blast counts, high-risk keryotypes and increased significantly in MDS-AML transformation. Furthermore, higher level of SALL4 expression was associated with worse survival rates and SALL4 level decreased following effective therapy.

Conclusions

To the best of our knowledge, this is the largest series and the first to report the expression pattern of SALL4 in detail in various subtypes of MDS in comparison to that of Bmi-1. We conclude that SALL4 is a potential molecular marker in predicting the prognosis of MDS.

Available only for authorised users

Tefferi A, Vardiman JW: Myelodysplastic syndromes. N Engl J Med. 2009, 361: 1872-1885. 10.1056/NEJMra0902908.CrossRefPubMed

Disperati P, Ichim CV, Tkachuk D, Chun K, Schuh AC, Wells RA: Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology. Leuk Res. 2006, 30: 233-239. 10.1016/j.leukres.2005.06.011.CrossRefPubMed

Sanz GF, Sanz MA, Greenberg PL: Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998, 83: 358-368.PubMed

Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997, 89: 2079-2088.PubMed

Garcia-Manero G: Prognosis of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2010, 2010: 330-337. 10.1182/asheducation-2010.1.330.CrossRefPubMed

Bains A, Luthra R, Medeiros LJ, Zuo Z: FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol. 2011, 135: 62-69. 10.1309/AJCPEI9XU8PYBCIO.CrossRefPubMed

Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL: Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011, 364: 2496-2506. 10.1056/NEJMoa1013343.PubMedCentralCrossRefPubMed

Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Gohring G, Hedlund A, Hast R, Schlegelberger B, Porwit A, Hellstrom-Lindberg E, Mufti GJ: TP53 mutations in low-risk myelodysplastic syndromes with del (5q) predict disease progression. J Clin Oncol. 2011, 29: 1971-1979. 10.1200/JCO.2010.31.8576.CrossRefPubMed

Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H, Yasunaga S, Takihara Y, Kimura A: Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood. 2006, 107: 305-308. 10.1182/blood-2005-06-2393.CrossRefPubMed

10.

Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A, Wichmann M, Gohring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Heuser M, Ganser A: Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011, 29: 2499-2506. 10.1200/JCO.2010.33.4938.CrossRefPubMed

11.

Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, Fulton R, Schmidt H, Kalicki-Veizer J, O’Laughlin M, Kandoth C, Baty J, Westervelt P, DiPersio JF, Mardis ER, Wilson RK, Ley TJ, Graubert TA: Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011, 25: 1153-1158. 10.1038/leu.2011.44.PubMedCentralCrossRefPubMed

12.

Chai L: The role of HSAL (SALL) genes in proliferation and differentiation in normal hematopoiesis and leukemogenesis. Transfusion. 2011, 51 (Suppl 4): 87S-93S.PubMedCentralCrossRefPubMed

13.

Cui W, Kong NR, Ma Y, Amin HM, Lai R, Chai L: Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Mod Pathol. 2006, 19: 1585-1592. 10.1038/modpathol.3800694.CrossRefPubMed

14.

Gao C, Kong NR, Chai L: The Role of Stem Cell Factor SALL4 in Leukemogenesis. Crit Rev Oncog. 2011, 16: 117-127. 10.1615/CritRevOncog.v16.i1-2.110.PubMedCentralCrossRefPubMed

15.

Gao C, Kong NR, Li A, Tatetu H, Ueno S, Yang Y, He J, Yang J, Ma Y, Kao GS, Tenen DG, Chai L: SALL4 is a key transcription regulator in normal human hematopoiesis. Transfusion. 2013, 53: 1037-1049. 10.1111/j.1537-2995.2012.03888.x.PubMedCentralCrossRefPubMed

16.

Jeong HW, Cui W, Yang Y, Lu J, He J, Li A, Song D, Guo Y, Liu BH, Chai L: SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes. PLoS One. 2011, 6: e18372-10.1371/journal.pone.0018372.PubMedCentralCrossRefPubMed

17.

Lu J, Ma Y, Kong N, Alipio Z, Gao C, Krause DS, Silberstein LE, Chai L: Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia. Leukemia. 2011, 25: 1211-1213. 10.1038/leu.2011.65.PubMedCentralCrossRefPubMed

18.

Ma Y, Cui W, Yang J, Qu J, Di C, Amin HM, Lai R, Ritz J, Krause DS, Chai L: SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood. 2006, 108: 2726-2735. 10.1182/blood-2006-02-001594.PubMedCentralCrossRefPubMed

19.

Yang J, Chai L, Gao C, Fowles TC, Alipio Z, Dang H, Xu D, Fink LM, Ward DC, Ma Y: SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008, 112: 805-813. 10.1182/blood-2007-11-126326.PubMedCentralCrossRefPubMed

20.

Yang J, Liao W, Ma Y: Role of SALL4 in hematopoiesis. Curr Opin Hematol. 2012, 19: 287-291. 10.1097/MOH.0b013e328353c684.CrossRefPubMed

21.

Yong K, Gao C, Lim J, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong C, Wong K-F, Lee S, Ravikumar S, Srivastava S, Tian X, Poon R, Fan S, Luk J, Dan Y, Salto-Tellez M, Chai L, Tenen D: Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med. 2013, 368: 2266-2276. 10.1056/NEJMoa1300297.PubMedCentralCrossRefPubMed

22.

Marquardt J, Thorgeirsson S: Sall4 in “stemness”-driven hepatocarcinogenesis. N Engl J Med. 2013, 368: 2316-2318. 10.1056/NEJMe1303026.CrossRefPubMed

23.

Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck A, Yamazaki Y, Wauthier E, Tajiri H, Miller L, Wang X, Reid L, Nakauchi H: Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology. 2013, 57: 1469-1483. 10.1002/hep.26159.CrossRefPubMed

24.

Xu D, TM O, Fowles TC, Fink LM, Ward DC, Mihm M, Waner M, Ma Y: Isolation, characterization, and in vitro propagation of infantile hemangioma stem cells and an in vivo mouse model. J Hematol Oncol. 2011, 4: 54-10.1186/1756-8722-4-54.PubMedCentralCrossRefPubMed

25.

Aguila JR, Liao W, Yang J, Avila C, Hagag N, Senzel L, Ma Y: SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. Blood. 2011, 118: 576-585. 10.1182/blood-2011-01-333641.PubMedCentralCrossRefPubMed

26.

Yang J, Aguila JR, Alipio Z, Lai R, Fink LM, Ma Y: Enhanced Self-Renewal of Hematopoietic Stem/Progenitor Cells Mediated by the Stem Cell Gene Sall4. J Hematol Oncol. 2011, 4: 38-10.1186/1756-8722-4-38.PubMedCentralCrossRefPubMed

27.

Schuster JA, Stupnikov MR, Ma G, Liao W, Lai R, Ma Y, Aguila JR: Expansion of hematopoietic stem cells for transplantation: current perspectives. Exp Hematol Oncol. 2012, 1: 12-10.1186/2162-3619-1-12.PubMedCentralCrossRefPubMed

28.

Iwama A, Oguro H, Negishi M, Kato Y, Morita Y, Tsukui H, Ema H, Kamijo T, Katoh-Fukui Y, Koseki H, van Lohuizen M, Nakauchi H: Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity. 2004, 21: 843-851. 10.1016/j.immuni.2004.11.004.CrossRefPubMed

29.

Lessard J, Sauvageau G: Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003, 423: 255-260. 10.1038/nature01572.CrossRefPubMed

30.

Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, Clarke MF: Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003, 423: 302-305. 10.1038/nature01587.CrossRefPubMed

31.

Yang J, Chai L, Liu F, Fink LM, Lin P, Silberstein LE, Amin HM, Ward DC, Ma Y: Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci U S A. 2007, 104: 10494-10499. 10.1073/pnas.0704001104.PubMedCentralCrossRefPubMed

32.

Nishino HT, Chang CC: Myelodysplastic syndromes: clinicopathologic features, pathobiology, and molecular pathogenesis. Arch Pathol Lab Med. 2005, 129: 1299-1310.PubMed

33.

Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC, De Vos J, Hernandez JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foa R: Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010, 28: 2529-2537. 10.1200/JCO.2009.23.4732.CrossRefPubMed

34.

Liu W, Li R, Sun J, Wang J, Tsai J, Wen W, Kohlmann A, Williams P: PQN and DQN: algorithms for expression microarrays. J theor biol. 2006, 243: 273-278. 10.1016/j.jtbi.2006.06.017.CrossRefPubMed

35.

Lin J, Qian J, Yao DM, Qian W, Yang J, Wang CZ, Chai HY, Ma JC, Deng ZQ, Li Y, Chen Q: Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome. Leuk Res. 2013, 37: 71-75. 10.1016/j.leukres.2012.10.014.CrossRefPubMed

36.

Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, Wang SA: Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 2008, 113: 3331-3340. 10.1002/cncr.23977.CrossRefPubMed

37.

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009, 114: 937-951. 10.1182/blood-2009-03-209262.CrossRefPubMed

38.

Gene Expression Omnibus dataset.http://www.ncbi.nlm.nih.gov/geo/,

Title: Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes
Authors: Fei Wang
Ye Guo
Qian Chen
Zhuo Yang
Ning Ning
Yujuan Zhang
Yonggang Xu
Xiaodong Xu
Chunrong Tong
Li Chai
Wei Cui
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-6-73

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing

Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation

Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases

DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population

Biomarkers for determining the prognosis in chronic myelogenous leukemia

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

Keynote webinar | Spotlight on antibody–drug conjugates in cancer